CoronaryAtlas logo
CoronaryAtlas
Neutrophil gelatinase-associated lipocalin (NGAL)
Pathway / Off-pathway / systemic markers

Neutrophil gelatinase-associated lipocalin (NGAL)

LCN2protein

NGAL is released by activated neutrophils and indicates acute kidney injury and renal dysfunction occurring as a hemodynamic consequence of MI.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleAcute kidney injury marker post-MI; reflects renal stress and systemic hemodynamic consequence, not atherothrombotic cascade mechanistic marker.
Also acts inMyocardial injury
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000148346

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
100
C — non-Type-I
59
A — assay feasibility
68
E — evidence strength
73
T1DI (composite)
35
Specificity differential (R−C)+40.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 3
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 1
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 9/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 32 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Plasma or urine
Collection tube
K2/K3-EDTA (lavender-top) · Sterile urine container
Method / principle
Immunoassay / POC
Reagent / substrate
Anti-NGAL antibody pair
Platform
Automated / POC (Abbott)
Turnaround · availability
Rapid · CE/research

Human genetic evidence

0.026
Open Targets association (STEMI)

Literature evidence(8)

Clinical trials(1)